Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 20, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 3 rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer’s disease
Phase 1b study showed dose-dependent and sustained reduction of tau protein in cerebrospinal fluid through open-label long-term extension (LTE) IONIS-MAPT Rx reduced aggregated tau pathology across all brain composites assessed starting as early as week 25 through week 100 CARLSBAD, Calif.
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks 35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in April CARLSBAD, Calif.
Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
If approved, tofersen will be the first treatment targeting a genetic cause of ALS and the next marketed Ionis-discovered antisense medicine FDA decision expected by April 25, 2023 CARLSBAD, Calif. , March 22, 2023 /PRNewswire/ — Ionis (Nasdaq: IONS) today announced the outcome of the U.S.
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
35-week data included in the filing demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints compared to external placebo group Eplontersen previously granted Orphan Drug Designation for transthyretin-mediated amyloidosis FDA